Qualigen Therapeutics, Inc.
QLGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10 | $6 | $5 | $19 |
| - Cash | $39 | $0 | $0 | $1 |
| + Debt | $3 | $4 | $1 | $0 |
| Enterprise Value | -$26 | $9 | $6 | $18 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$2 | -$3 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$2 | -$3 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.73 | -1 | -1.82 | -0.19 |
| % Growth | -73% | 45.1% | -857.9% | – |
| Operating Cash Flow | -$2 | -$1 | -$2 | -$2 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$1 | -$2 | -$2 |